NCT06668363 Enhancing HIV Prevention and Reducing Alcohol Use Among People Receiving STI Care in Lilongwe, Malawi
| NCT ID | NCT06668363 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of North Carolina, Chapel Hill |
| Condition | Alcohol Consumption |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2024-12-12 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2024-12-12 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Purpose: To evaluate short-term efficacy and implementation of Treat4All, an alcohol reduction evidence-based intervention, for decreasing heavy drinking and optimizing HIV outcomes (viral suppression among People with HIV (PWH); Pre-exposure prophylaxis (PrEP) use among those at high risk of HIV) Participants: Approximately 160 participants aged 18 years or older will be enrolled into this study. Eligible participants will be recruited from two groups of individuals: Persons at risk of HIV: Individuals receiving (STI) care who report recent heavy drinking (n=80) and no recent use of PrEP. Persons with HIV: Individuals with HIV who report recent heavy drinking and either a history of unsuppressed viral load or recent suboptimal adherence to ART (n=80). Procedures (methods): Pilot two-arm randomized controlled trial (1:1; Treat4All Intervention vs Usual Care)
Eligibility Criteria
Inclusion Criteria: * Men and women age 18 years or older. * Receiving care at Bwaila STI clinic. * Report recent heavy drinking (greater than or equal to 4 drinks a day in the past 30 days for men and greater than or equal to 3 drinks a day in the past 30 days for women * Willing to receive an HIV test at study enrollment, if not previously diagnosed Report not taking ART, recent suboptimal adherence to ART, or recent history of unsuppressed HIV viral load \[for PWH\] or no recent oral PrEP use (self-reported taking no PrEP pills in past 7 days) \[for those at risk of HIV\] * Plan to reside in the Lilongwe area for at least 6 months. * Not participating in other HIV or alcohol programs * Ability and willingness of participant to provide informed consent. * Willingness to provide contact/locator information to be contacted for follow up study activities. Exclusion Criteria: * Unable to participate in study activities due to psychological disturbance, cognitive impairment, or threatening behavior * Pregnant or breastfeeding * At risk of experiencing alcohol-related withdrawal symptoms * Acute physical or mental illness, including suicidal thoughts or behaviors * Participating in in other HIV or alcohol programs * Active drug dependence that would interfere with adherence to study requirements. * History of using injectible PrEP * Any other condition that in the opinion of the study investigator would compromise the safety of the study participant or study staff or would prevent proper conduct of the study.
Contact & Investigator
Angela Parcesepe, PhD, MPH, MSW
PRINCIPAL INVESTIGATOR
University of North Carolina, Chapel Hill
Frequently Asked Questions
Who can join the NCT06668363 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alcohol Consumption. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06668363 currently recruiting?
Yes, NCT06668363 is actively recruiting participants. Contact the research team at angela_parcesepe@unc.edu for enrollment information.
Where is the NCT06668363 trial being conducted?
This trial is being conducted at Lilongwe, Malawi.
Who is sponsoring the NCT06668363 clinical trial?
NCT06668363 is sponsored by University of North Carolina, Chapel Hill. The principal investigator is Angela Parcesepe, PhD, MPH, MSW at University of North Carolina, Chapel Hill. The trial plans to enroll 160 participants.